Protagenic Therapeutics 10-K: Going Concern, Nasdaq Delisting, and $7.3M Unwind Gain
PTIX has more than doubled off its 52-week low of $0.128 on light trading volume (0.2× avg).
Summary
Protagenic Therapeutics filed its 10-K, disclosing a going concern warning, Nasdaq delisting, material weaknesses, and a $7.3M gain from unwinding its Phytanix Bio merger.
Key Events · Earnings and Guidance · PTIX
-
Going Concern Warning
Cash of $1.5M as of March 31, 2026, funds operations only through Q3 2026. The company needs additional capital within 12 months.
-
Nasdaq Delisting
Common stock delisted from Nasdaq effective January 5, 2026, now trading on OTCQB. Company is evaluating steps to regain compliance.
-
Material Weaknesses
Management identified material weaknesses in internal controls over financial reporting, including lack of segregation of duties and ineffective risk assessment.
-
Phytanix Bio Unwind
Reverse merger with Phytanix Bio was unwound on February 17, 2026, resulting in a $7.3M gain on disposal of subsidiary.
Analysis · PTIX · Life Sciences
The annual report reveals a going concern warning with cash only through Q3 2026, material weaknesses in internal controls, and delisting from Nasdaq. The company also unwound its reverse merger with Phytanix Bio, recognizing a $7.3M gain, and implemented a restructuring plan to cut $8M in annual expenses. These are critical disclosures for a micro-cap biotech with a $0.36 stock price.
At the time of this filing, PTIX was trading at $0.36 on OTC in the Life Sciences sector, with a market capitalization of approximately $651.7K. The 52-week trading range was $0.13 to $6.20. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.